FY24 Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital Prospective Payment System (LTCH) Proposed Rule
Download to see features of the proposed rule.
Download to see features of the proposed rule.
A pharma company needed to evaluate the likelihood that drug compendia would positively rate an off-label dosage of an FDA-approved medication to support additional payer coverage.
A biopharma company needed an appropriate pricing model for a new tablet formulation of a successful existing infusion.
Biopharmaceutical companies engaged Magnolia to help them understand the implications of the Inflation Reduction Act of 2022 and develop long-term strategic plans to adjust for the sweeping market changes it will cause.
A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies
A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics
A development-stage biopharma company engaged Magnolia to help put in place an overarching launch road map for a drug that had just received positive phase 3 data
A biopharma company needed an inpatient coding analysis for their new medication
A pharmaceutical company offering a hub designed to address patient medication access challenges received customer feedback expressing dissatisfaction from both patients and providers